Business Development Associate, Asimov
Intelligent genetic design platform
Open for applications
Intelligent genetic design platform
21-100 employees
Open for applications
21-100 employees
Company mission
To empower the genetic designers who are building the future.
Role
Who you are
- Professional experience: At least 3 years’ experience in a business development or sales role, ideally within the B2B biopharmaceutical tools and/or services sector
- Industry knowledge: A deep understanding of the biotherapeutics manufacturing landscape
- Networking skills: Ability to rapidly build rapport and effectively communicate the benefits of partnering with Asimov. You have an established and expanding network within the biopharma services and tools market
- Customer relationship expertise: Proven track record of growing long-term relationships with clients
- Technical acumen: Knowledge of cell line development and upstream process development for biologics and/or viral vectors
- Educational background: A Master's degree in a biologics-based discipline is preferred. Alternatively, a Bachelor's degree in Life Sciences coupled with relevant experience will be considered
What the job involves
- We’re searching for a Business Development Associate to join our Commercial Team
- As a Business Development Associate, you’ll be responsible for building market awareness of Asimov and driving new business for the company
- You’ll be able to grow within a business development role at an agile, forward-thinking synthetic biology startup with a global reach
- This is an opportunity to help build the future of biological engineering
- Drive revenue growth: Proactively source and secure business opportunities with biopharma companies ranging from virtual organisations to big pharma in order to drive significant revenue growth
- Customer relationship development: Play a central role in building and nurturing relationships with clients, focusing on customer centricity
- Communicate Asimov’s platform technologies: Effectively convey the technical and commercial benefits of our offerings to potential clients
- Structure deals: Work closely with the broader Commercial Team to develop deal structures that maximise value for all parties involved
- Engage with industry: Represent Asimov at industry conferences, network with potential partners, and grow awareness of our technologies and services
Our take
Despite the many recent breakthroughs in medicine, drug manufacturing remains a lengthy and costly process that is difficult to scale. Asimov seeks to combat this with its intelligent design suite for synthetic biologists, that leverages computer-aided design to help design, simulate, and optimise genetic systems more reliably.
Asimov's platform consists of a fully integrated suite of cells, genes, and software that can be implemented in every step of the therapeutics creation process from initial design through to analysis. By accelerating the speed at which biologists can test and improve their drugs, the company has hopes to help bring innovative treatments to market faster and thus advance the standard of treatment for patients.
Having secured considerable funding, Asimov is looking to scale its business in biologics, advanced cell/gene therapies, and RNA. It will also use the investment to expand research and development into new areas of synthesis, as well as grow its team.
Steph
Company Specialist at Welcome to the Jungle
Insights
41% employee growth in 12 months
Company
Funding (last 2 of 3 rounds)
Jan 2023
$175m
SERIES B
Dec 2019
$25m
SERIES A
Total funding: $204.7m
Company values
- Recombination - Genetic engineering recombines genes from different species into new systems. At Asimov, we're working toward an ambitious mission that will only be possible by recombining disciplines, backgrounds, and perspectives
- Mission first - Our prime directive is to radically advance humanity’s ability to design living systems, enabling biological technologies with outsized societal benefit. Every decision flows from this mission
- Continuous learning - Biotech is advancing rapidly – we’re surfing that wave and also helping drive it forward. A curiosity to learn new things and an ability to teach other team members is critical to living at the cutting edge
- Thoughtful communication - Our team comes from varied technical domains; we constantly strive to consider people's backgrounds, tailoring our communication to maximize understanding and alignment
- Evolution - As we grow, we’re unafraid to evolve, adapt, and improve all aspects of our company's technology, products, and operations. We must avoid getting trapped in a local optimum
Company HQ
West Fens, Boston, MA
Articles
Leadership
Chris Voigt
(Co-Founder)Board Member at the Novo Nordisk Foundation, MIT Professor, and Co-Founder of Pivot Bio.
Douglas Densmore
(Co-Founder)Professor at Boston University. Previously co-founded BioSens8 and Lattice Automation.
Share this job